[Antithrombotic drugs].
An increase in plasma fibrinogen content and a decrease in level of antithrombin III in plasma with ageing may cause a thrombotic tendency in the elderly, although the main cause of thrombosis in the aged is atherosclerotic change seen in these subjects. Coagulability of blood is maintained in the so-called therapeutic range in aged patients receiving oral anticoagulant, as well as in younger subjects, however, it has been pointed out that there is an increasing risk of hemorrhage, especially of intracranial hemorrhage, with advancing age. Intracranial hemorrhage is not necessarily a rare complication of anti-platelet or thrombolytic therapy in the aged. Another hazard of aspirin therapy in the aged is the abrupt development of peptic ulcer. The authors administered 40 mg of aspirin per day to ten volunteers. In these subjects, platelets in the venous blood taken in a glass tube were strongly stimulated by coagulating whole blood in the tube for 60 minutes at 37 degrees C. Under this condition, arachidonic acid in platelets was converted to thromboxane B2, which is a stable metabolite of thromboxane A2 that causes platelet aggregation and vasoconstriction to accelerate thrombus formation. After ingestion of the minidose aspirin for one week, the concentration of thromboxane B2 in the serum (not in the plasma) of the volunteers decreased to 7% of the values determined before the administration of the drug, because of inhibition of cyclo-oxygenase in the platelets by aspirin. However, concentration of 6-keto-PGF1 alpha, which is a stable metabolite of prostacyclin that originates from arachidonic acid by cyclo-oxygenase in the vessel wall, did not markedly decrease after the treatment with aspi2+ t-PA and hybrid of t-PA and scu-PA in the aged are discussed. If antithrombotic therapy is always safe in the aged, it may be rational and economical to select subjects predisposed to thrombosis among patients with atherosclerosis. Determination of levels of fibrinogen, beta-thromboglobulin and/or thrombin-antithrombin III complex in plasma may be useful to predict thrombosis.